Zhengfang Yi
YOU?
Author Swipe
View article: Supplementary Methods from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer
Supplementary Methods from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer Open
Supplementary Methods
View article: Supplementary Tables S1-S6 from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer
Supplementary Tables S1-S6 from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer Open
Table S1. List of antibodies used and their technical information Table S2. The sequence of Real-time PCR primersTable S3. The sequence of shRNAs for silencing STAT3 Table S4. The sequence of ChromatinImmunoprecipitation (Ch-IP) PCRTable S…
View article: Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase
Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase Open
Dopamine receptor agonist (DA)-resistant prolactinoma presents a significant clinical challenge, highlighting the need for novel therapeutic strategies. Deguelin is a rotenoid compound derived from several plant species with unique antitum…
View article: A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression
A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression Open
Neuroblastoma, a prevalent and lethal extracranial solid tumor in childhood, remains a significant challenge in pediatric oncology worldwide. High-risk neuroblastoma (HR-NB) is particularly aggressive and linked to a poor prognosis due to …
View article: Corrigendum to “Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer” [Neoplasia. 2014 Aug;16(8):665-77]
Corrigendum to “Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer” [Neoplasia. 2014 Aug;16(8):665-77] Open
View article: Selectively targeting BCL6 using a small-molecule inhibitor is a potential therapeutic strategy for glioblastoma
Selectively targeting BCL6 using a small-molecule inhibitor is a potential therapeutic strategy for glioblastoma Open
Glioblastoma multiforme (GBM) is the deadliest form of brain tumor, and effective treatments are lacking. Thus, a new generation of effective treatments is urgently needed. B-cell lymphoma 6 (BCL6) is a transcription factor that functions …
View article: Research on high-resolution reconstruction methods for microlens array snapshot hyperspectral microscopy system combining transfer learning and data decomposition-reconstruction
Research on high-resolution reconstruction methods for microlens array snapshot hyperspectral microscopy system combining transfer learning and data decomposition-reconstruction Open
The microlens array snapshot hyperspectral microscopy system has significant potential in dynamic microscopic monitoring due to its ability to rapidly acquire three-dimensional data cubes without scanning. However, its low spatial resoluti…
View article: Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Targeting BCMA in multiple myeloma: designs, challenges, and future directions Open
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has…
View article: Figure S4 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S4 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S4. Activation effect of BI3802, FX1 and WK692 on downstream gene of BCL6 at 10 µM. (*, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control).
View article: Supplementary Table from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Supplementary Table from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Supplementary Table 1. Main pharmacokinetic parameters of WK692 after oral administration or intravenous injection in rats (mean ± SD).
View article: Figure S2 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S2 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S2. WK692 specifically inhibits BCL6 but not other BTB-ZF Proteins. Reporter assays were performed to test the activity of WK692 with BCL6, Kaiso and PLZF. (***, P < 0.001 versus control).
View article: Figure S1 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S1 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S1. Chemical structures of FX1, BI3802 and WK692.
View article: Supplementary Methods from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Supplementary Methods from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Supplementary Methods
View article: Figure S6 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S6 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S6. WK692 targets BCL6-BTB domain. (A) Computer docking assay predicted that WK692 bound to the BCL6-BTB domain. (B) The binding affinities were measured by SPR assay. (C) SUDHL4 shBCL6-1/shBCL6-2 cells were infected with lentivirus…
View article: Data from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Data from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
The B-cell lymphoma 6 (BCL6) transcription factor plays a key role in the establishment of germinal center (GC) formation. Diffuse large B-cell lymphoma (DLBCL) originates from the GC reaction due to dysregulation of BCL6. Disrupting BCL6 …
View article: Figure S5 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S5 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S5. Viability of SUDHL4 and Farage cells transduced with shBCL6 or shScr was measured by CCK8 assay.
View article: Figure S7 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S7 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S7. H&E staining of liver, spleen, lung and kidney from subcutaneous tumor xenografts mice treated with FX1 and WK692. Scale bars, 50 μm.
View article: Figure S3 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Figure S3 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma Open
Figure S3. Quantitative ChIP assay was used to detect the enrichment of CDKN1A, CXCR4 and negative control region by NCOR in SUDHL4 cells exposed to 5 μM WK692 for 24 h. (*, P < 0.05 versus control)
View article: Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression
Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression Open
2 panel, one of the mice from the N4 10 mg/kg group was inadvertently duplicated with a mouse from the C188-9 group in week 2. Figures 6A have now been corrected as shown below.
View article: Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment
Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment Open
Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. Unfortunately, targeting STAT3 with small molecules has proven to be very challenging, and for full activation of STAT3, the cooperative…
View article: An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo
An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo Open
Background and Purpose: The transcription factor B cell lymphoma 6 (BCL6) is an oncogenic driver of diffuse large B cell lymphoma (DLBCL). Blocking the protein-protein interactions of BCL6 and its corepressors has been proposed as an effec…
View article: Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer
Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer Open
Myoferlin (MYOF) mediates the growth and metastasis of various cancers as an emerging therapeutic target by regulating exocytosis and endocytosis. However, the previously reported MYOF inhibitor, 6y, failed to be a favorable candida…
View article: Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer
Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer Open
Ovarian cancer is one of the tumors with the highest fatality rate among gynecological tumors. The current 5-year survival rate of ovarian cancer is <35%. Therefore, more novel alternative strategies and drugs are needed to treat ovarian c…
View article: Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4
Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4 Open
View article: A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia
A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia Open
BCL6 is a transcriptional repressor that regulates multiple genes involved in immune cell differentiation, DNA damage repair, cell cycle, and apoptosis, and is a carcinogenic factor in acute myeloid leukemia (AML). AML is one of the four m…
View article: Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for Glioblastoma
Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for Glioblastoma Open
Glioblastoma (GBM) is the deadliest brain malignancy without effective treatments, and novel effective treatments are urgently needed. B cell lymphoma 6 (BCL6) is a transcription factor that stops cell death in response to DNA damage, prim…
View article: Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma
Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma Open
Natural killer/T‐cell lymphoma (NKTL) is an uncommon malignancy with poor prognosis and limited therapeutic options. Activating mutations of signal transducer and activator of transcription 3 (STAT3) are frequently found in patients with N…
View article: Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer Open
Introduction Due to the difficulty of early diagnosis, nearly 70% of ovarian cancer patients are first diagnosed at an advanced stage. Thus, improving current treatment strategies is of great significance for ovarian cancer patients. Fast-…
View article: Supplementary Figure 1 from Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer
Supplementary Figure 1 from Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer Open
PDF file - 2.3MB
View article: Supplementary Figure 1 from Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer
Supplementary Figure 1 from Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer Open
PDF file - 2.3MB